Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge
- Food and Drug Administration, Silver Spring, MD (United States)
- United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD (United States)
- United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD (United States); Univ. of New Mexico, Albuquerque, NM (United States)
- Rockefeller Univ., New York, NY (United States)
Ebola virus (EBOV), a member of the Filoviridae that can cause severe hemorrhagic fever in humans and nonhuman primates, poses a significant threat to the public health. Currently, there are no licensed vaccines or therapeutics to prevent and treat EBOV infection. Several vaccines based on the EBOV glycoprotein (GP) are under development, including vectored, virus-like particles, and protein-based subunit vaccines. We previously demonstrated that a subunit vaccine containing the extracellular domain of the Ebola ebolavirus (EBOV) GP fused to the Fc fragment of human IgG1 (EBOVgp-Fc) protected mice against EBOV lethal challenge. Here, we show that the EBOVgp-Fc vaccine formulated with QS-21, alum, or polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose (poly-ICLC) adjuvants induced strong humoral immune responses in guinea pigs. The vaccinated animals developed anti-GP total antibody titers of approximately 105–106 and neutralizing antibody titers of approximately 103 as assessed by a BSL-2 neutralization assay based on vesicular stomatitis virus (VSV) pseudotypes. The poly-ICLC formulated EBOVgp-Fc vaccine protected all the guinea pigs against EBOV lethal challenge performed under BSL-4 conditions whereas the same vaccine formulated with QS-21 or alum only induced partial protection. Vaccination with a mucin-deletedEBOVgp-Fc construct formulated with QS-21 adjuvant did not have a significant effect in anti-GP antibody levels and protection against EBOV lethal challenge compared to the full-lengthGP construct. The bulk of the humoral response induced by the EBOVgp-Fc vaccine was directed against epitopes outside the EBOV mucin region. Our findings indicate that different adjuvants can eliciting varying levels of protection against lethal EBOV challenge in guinea pigs vaccinated with EBOVgp-Fc,and suggest that levels of total anti-GP antibodies elicit by protein-based GP subunit vaccines do not correlate with protection. In conclusion, our data further support the development of Fc fusions of GP as a candidate vaccine for human use.
- Research Organization:
- Food and Drug Administration, Silver Spring, MD (United States)
- Sponsoring Organization:
- USDOE
- Grant/Contract Number:
- Y1-AI-0664-01; Intramural; DTRA IAA 11005IA-3333-Basic
- OSTI ID:
- 1377872
- Journal Information:
- PLoS ONE, Vol. 11, Issue 9; ISSN 1932-6203
- Publisher:
- Public Library of ScienceCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Ebola and Marburg virus vaccines
|
journal | April 2017 |
Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates
|
journal | May 2019 |
Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus
|
journal | August 2018 |
Saponins from Quillaja saponaria and Quillaja brasiliensis: Particular Chemical Characteristics and Biological Activities
|
journal | January 2019 |
A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice
|
journal | December 2019 |
Similar Records
The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys
Candidate mosaic proteins for a pan-filoviral cytotoxic T-Cell lymphocyte vaccine